Stifel Cuts PT on Momenta Pharma (MNTA) to $20; Glatopa Court Battle Becomes Increasingly Important
Tweet Send to a Friend
Stifel trims its price target on Buy-rated Momenta Pharmaceuticals (Nasdaq: MNTA) from $29 to $20 following Q4 results reported earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
